CSL Limited Stock

Equities

CSL

AU000000CSL8

Pharmaceuticals

Market Closed - Australian S.E. 02:10:53 2024-05-31 am EDT 5-day change 1st Jan Change
280.1 AUD +0.64% Intraday chart for CSL Limited -0.29% -2.29%
Sales 2024 * 14.72B 22.12B Sales 2025 * 15.93B 23.95B Capitalization 89.87B 135B
Net income 2024 * 2.71B 4.08B Net income 2025 * 3.26B 4.9B EV / Sales 2024 * 6.77 x
Net Debt 2024 * 9.82B 14.76B Net Debt 2025 * 8.65B 13.01B EV / Sales 2025 * 6.18 x
P/E ratio 2024 *
32.9 x
P/E ratio 2025 *
27.4 x
Employees 32,065
Yield 2024 *
1.43%
Yield 2025 *
1.66%
Free-Float 99.53%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.64%
1 week-0.29%
1 month+1.21%
3 months-2.15%
6 months+6.81%
Current year-2.29%
More quotes
1 week
275.04
Extreme 275.04
284.50
1 month
273.87
Extreme 273.87
287.25
Current year
265.14
Extreme 265.14
306.42
1 year
228.65
Extreme 228.65
312.99
3 years
228.65
Extreme 228.65
319.78
5 years
200.37
Extreme 200.37
342.75
10 years
63.77
Extreme 63.77
342.75
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 19-05-31
Director of Finance/CFO 59 20-09-30
Chief Tech/Sci/R&D Officer 62 20-09-30
Members of the board TitleAgeSince
Director/Board Member 69 19-12-08
President 68 90-06-30
Director/Board Member 61 21-08-18
More insiders
Date Price Change Volume
24-05-31 280.1 +0.64% 4,571,806
24-05-30 278.3 +0.04% 516,644
24-05-29 278.2 -1.33% 794,478
24-05-28 282 +0.47% 637,279
24-05-27 280.6 -0.10% 371,943

Delayed Quote Australian S.E., May 31, 2024 at 02:10 am EDT

More quotes
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
186 USD
Average target price
202.7 USD
Spread / Average Target
+8.98%
Consensus